The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1 trial and pharmacokinetic study of RRx-001, a novel ROS-mediated pan-epigenetic agent.
Tony R. Reid
No relevant relationships to disclose
Bryan Oronsky
Employment or Leadership Position - RadioRx
Consultant or Advisory Role - RadioRx (I,U); RadioRx (U)
Stock Ownership - RadioRx (I); RadioRx
Jeffrey R. Infante
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Curtis Scribner
Consultant or Advisory Role - RadioRx
Susan Jane Knox
Consultant or Advisory Role - RadioRx
Stock Ownership - RadioRx
Honoraria - RadioRx
Research Funding - RadioRx
Janet L. Stephens
Employment or Leadership Position - RadioRx
Stock Ownership - RadioRx
Gary Fanger
Consultant or Advisory Role - RadioRx (U)
Jan Scicinski
Employment or Leadership Position - RadioRx
Stock Ownership - RadioRx